canakinumab and juvenile idiopathic arthritis (JIA) Archives

Abstract Number: 3 • Pediatric Rheumatology Symposium 2017
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Rayfel Schneider⁴, Isabelle Koné-Paut⁵, Kenneth N. Schikler⁶, Katherine Marzan⁴, Nico Wulffraat², Shai Padeh⁷, Vyacheslav Chasnyk⁷, Carine Wouters⁷, Jasmin B. Kuemmerle-Deschner⁷, Tilmann Kallinich⁷, Bernard Lauwerys⁸, Elie Haddad⁴, Evgeny L Nasonov⁷, Maria Trachana⁷, Olga Vougiouka⁷, Karolynn Leon⁹, Antonio Speziale¹⁰, Karine Lheritier¹⁰, Eleni Vritzali¹¹, Alberto Martini⁷ and Daniel Lovell⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴PRCSG, Cincinnati, OH, ⁵Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁶PRCSG, Cincinatti, OH, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic arthritis…
Abstract Number: 44 • Pediatric Rheumatology Symposium 2017
Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Isabelle Koné-Paut⁴, Katherine Marzan⁵, Nico Wulffraat², Rayfel Schneider⁵, Shai Padeh⁶, Vyacheslav Chasnyk⁶, Carine Wouters⁶, Jasmin B. Kuemmerle-Deschner⁶, Tilmann Kallinich⁶, Bernard Lauwerys⁷, Elie Haddad⁵, Evgeny L Nasonov⁶, Maria Trachana⁶, Olga Vougiouka⁶, Karolynn Leon⁸, Eleni Vritzali⁹, Karine Lheritier¹⁰, Alberto Martini⁶ and Daniel Lovell⁵, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁵PRCSG, Cincinnati, OH, ⁶PRINTO-Istituto Gaslini, Genova, Italy, ⁷Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The management of SJIA with biological therapies is aimed to achieve and maintain clinical remission (CR), and accordingly taper corticosteroids (CS). Canakinumab (CAN) demonstrated…

Abstracts tagged "canakinumab and juvenile idiopathic arthritis (JIA)"

Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study

Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study